Caladrius Biosciences, Inc. Announces Executive Changes
November 17, 2020 at 04:09 pm EST
Share
On November 11, 2020, Douglas W. Losordo, M.D., Executive Vice President, Global Head of Research & Development and Chief Medical Officer of Caladrius Biosciences, Inc. notified the Company of his intent to resign from all positions held with the Company in order to pursue other career opportunities. Dr. Losordo delivered his resignation notice effective November 12, 2020. Effective immediately, industry veteran Robert Honigberg, M.D., has been retained to assume the role of interim CMO and will provide continuity of leadership and support for the Company's clinical and regulatory activities. Throughout the course of his career, Dr. Honigberg has served in the role of senior medical affairs officer at several companies including Shire Plc., CardioDx, Inc., GE Healthcare, Ethicon Endo-Surgery and Ortho Biotech, both Johnson & Johnson operating companies, Flexion Therapeutics, Inc., Liposcience, Inc., and Schering-Plough Corporation.
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.
LISATA THERAPEUTICS, INC. 
